Security
Harmony Biosciences Holdings, Inc. Common Stock · HRMY
HRMYNASDAQCommon stockCurrentCIK 1802665Updated Nov 17, 2026
HRMY price & chart
Loading TradingView…
NASDAQ:HRMY on TradingView ↗About the company
Harmony Biosciences is developing and commercializing innovative medicines for both rare and broad CNS disorders, and we are becoming an enduring leader in neuroscience. Our first medicine, WAKIX® (pitolisant), is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness or cataplexy in patients 6 years of age and older with narcolepsy. Its launch ranks among the most successful in the history of orphan drugs. Building on our success and profitability, we are continuing to advance our novel clinical-stage pipeline, led by BP-205, an investigational orexin-2 receptor agonist with best-in-class potential across a broad range of CNS disorders. With a strong balance sheet, we have the capacity and conviction to pursue strategic business development opportunities. Harmony is guided by an unwavering commitment to patients and driven to create long-term value for shareholders. For more information, visit: www.harmonybiosciences.com.
In the news
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress ↗
Recent filings
SCHEDULE 13G - filed by AMERICAN CENTURY INVESTMENT MANAGEMENT INC regarding Harmony Biosciences Holdings, Inc.
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Show 5 more recent filings
144 filing
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
SCHEDULE 13G - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding Harmony Biosciences Holdings, Inc.
Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 2.02, 5.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,208,218,000Source | 928,135,000Source | 1,373,084,000Source | 1,108,008,000Source | 858,383,000Source | 1,271,824,000Source | 1,055,535,000Source | 846,985,000Source | 1,271,631,000Source | 999,200,000Source | 811,448,000Source | 673,870,000Source |
| Property, Plant and Equipment, NetUSD | 1,440,000Source | 750,000Source | — | 1,376,000Source | 754,000Source | — | 1,378,000Source | 213,000Source | — | 1,257,000Source | 371,000Source | 573,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 95,380,000Source | 119,225,000Source | 77,496,000Source | 101,341,000Source | 125,186,000Source | 83,457,000Source | 107,302,000Source | 131,147,000Source | 89,418,000Source | 113,263,000Source | 137,108,000Source | 160,953,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 646,999,000Source | 387,367,000Source | 549,769,000Source | 546,050,000Source | 317,296,000Source | 589,398,000Source | 488,998,000Source | 332,981,000Source | 752,502,000Source | 453,001,000Source | 311,660,000Source | 243,784,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 100,651,000Source | 81,502,000Source | 110,995,000Source | 92,981,000Source | 83,157,000Source | 108,222,000Source | 105,969,000Source | 79,719,000Source | 96,787,000Source | 83,033,000Source | 74,140,000Source | 54,740,000Source |
| Inventory, NetUSD | 6,882,000Source | 6,915,000Source | 6,360,000Source | 6,100,000Source | 5,643,000Source | 5,281,000Source | 6,384,000Source | 5,857,000Source | 5,357,000Source | 7,198,000Source | 5,363,000Source | 4,297,000Source |
| Assets, CurrentUSD | 838,800,000Source | 522,405,000Source | 814,334,000Source | 691,354,000Source | 458,344,000Source | 778,817,000Source | 642,692,000Source | 479,503,000Source | 907,014,000Source | 579,252,000Source | 451,070,000Source | 400,285,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,228,000Source | 2,320,000Source | 5,839,000Source | 1,277,000Source | 2,508,000Source | 5,388,000Source | 1,726,000Source | 3,046,000Source | 5,344,000Source | 2,122,000Source | 2,344,000Source | 2,312,000Source |
| Other Assets, NoncurrentUSD | 9,692,000Source | 6,247,000Source | 29,821,000Source | 5,465,000Source | 6,465,000Source | 26,433,000Source | 5,939,000Source | 6,969,000Source | 18,373,000Source | 5,886,000Source | 6,298,000Source | 2,798,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 373,095,000Source | 331,331,000Source | 373,841,000Source | 334,928,000Source | 319,800,000Source | 361,475,000Source | 335,010,000Source | 331,591,000Source | 401,413,000Source | 340,045,000Source | 344,456,000Source | 271,032,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Retained Earnings (Accumulated Deficit)USD | 138,417,000Source | -47,259,000Source | 268,822,000Source | 87,552,000Source | -93,352,000Source | 193,391,000Source | 47,776,000Source | -104,943,000Source | 160,903,000Source | 2,216,000Source | -143,277,000Source | -272,130,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 357,000Source | 499,000Source | -727,000Source | 239,000Source | -234,000Source | -413,000Source | 245,000Source | -171,000Source | 346,000Source | 66,000Source | 2,000Source | -151,000Source |
| Stockholders' Equity Attributable to ParentUSD | 835,123,000Source | 596,804,000Source | 999,243,000Source | 773,080,000Source | 538,583,000Source | 910,349,000Source | 720,525,000Source | 515,394,000Source | 870,218,000Source | 659,155,000Source | 466,992,000Source | 402,838,000Source |
| Additional Paid in Capital, Common StockUSD | 696,348,000Source | 643,563,000Source | 731,147,000Source | 685,288,000Source | 632,168,000Source | 717,370,000Source | 672,503,000Source | 620,507,000Source | 708,968,000Source | 656,872,000Source | 610,266,000Source | 675,118,000Source |
| Liabilities and EquityUSD | 1,208,218,000Source | 928,135,000Source | 1,373,084,000Source | 1,108,008,000Source | 858,383,000Source | 1,271,824,000Source | 1,055,535,000Source | 846,985,000Source | 1,271,631,000Source | 999,200,000Source | 811,448,000Source | 673,870,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 223,403,000Source | 161,279,000Source | 234,070,000Source | 180,135,000Source | 146,582,000Source | 217,340,000Source | 175,118,000Source | 154,253,000Source | 252,132,000Source | 175,082,000Source | 163,781,000Source | 78,884,000Source |
| Operating Lease, Liability, CurrentUSD | 825,000Source | 1,532,000Source | 1,455,000Source | 846,000Source | 1,786,000Source | 1,267,000Source | 1,148,000Source | 1,793,000Source | 1,073,000Source | 1,318,000Source | 1,437,000Source | 1,614,000Source |
| Accounts Payable, CurrentUSD | 26,341,000Source | 10,532,000Source | 21,684,000Source | 28,301,000Source | 22,683,000Source | 28,600,000Source | 17,459,000Source | 15,144,000Source | 17,693,000Source | 13,744,000Source | 17,730,000Source | 3,786,000Source |
| Operating Lease, Liability, NoncurrentUSD | 403,000Source | 863,000Source | 4,775,000Source | 432,000Source | 854,000Source | 4,528,000Source | 634,000Source | 1,276,000Source | 4,512,000Source | 822,000Source | 1,082,000Source | 975,000Source |
| Other Liabilities, NoncurrentUSD | 1,186,000Source | 2,205,000Source | 5,810,000Source | 1,448,000Source | 1,796,000Source | 5,321,000Source | 1,710,000Source | 2,342,000Source | 5,618,000Source | 1,947,000Source | 2,109,000Source | 2,501,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 109,673,000Source | 169,128,000Source | — | 91,644,000Source | 150,107,000Source | — | 91,699,000Source | 191,039,000Source | 120,640,000Source | — | 59,942,000Source |
| Long-term Debt, Current MaturitiesUSD | 20,000,000Source | 15,000,000Source | 20,000,000Source | 18,750,000Source | 15,000,000Source | 20,000,000Source | 17,500,000Source | 15,000,000Source | 20,000,000Source | 16,250,000Source | 15,000,000Source | 2,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 148,506,000Source | 167,847,000Source | 133,961,000Source | 153,345,000Source | 171,422,000Source | 138,814,000Source | 158,182,000Source | 174,996,000Source | 143,663,000Source | 163,016,000Source | 178,566,000Source | 189,647,000Source |
| Short-term InvestmentsUSD | 25,582,000Source | 23,109,000Source | 118,022,000Source | 19,224,000Source | 29,614,000Source | 51,520,000Source | 17,955,000Source | 39,369,000Source | 22,838,000Source | 14,185,000Source | 41,800,000Source | 79,331,000Source |
| Long-term Debt, Excluding Current Maturities | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 32,488,000Source | 45,560,000Source | 158,687,000Source | 145,493,000Source | 128,853,000Source | 181,468,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 10,620,000Source | 12,499,000Source | 44,895,000Source | 42,602,000Source | 31,705,000Source | 26,173,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 11,435,000Source | 22,936,000Source | 13,754,000Source | 8,893,000Source | 19,400,000Source | 19,897,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -76,000Source | -814,000Source | -1,841,000Source | 1,835,000Source | 1,066,000Source | -135,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 40,699,000Source | -29,298,000Source | -14,994,000Source | 10,423,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 27,760,000Source | 33,987,000Source | 348,199,000Source | 219,821,000Source | 219,387,000Source | 144,466,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | 36,967,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -183,646,000Source | 2,362,000Source | -39,649,000Source | -67,484,000Source | -46,439,000Source | -141,832,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 128,000Source | 310,000Source | 1,153,000Source | 312,000Source | 172,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 2,565,000Source | 1,308,000Source | 3,004,000Source | 2,497,000Source | 514,000Source | — |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 100,000,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -7,218,000Source | -352,000Source | -9,049,000Source | -10,996,000Source | -105,552,000Source | 6,841,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 5,000,000Source | 3,750,000Source | 16,250,000Source | 15,000,000Source | 4,750,000Source | 2,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -163,104,000Source | 35,997,000Source | 299,501,000Source | 141,341,000Source | 67,396,000Source | 9,475,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 647,269,000Source | 387,637,000Source | 550,039,000Source | 546,320,000Source | 589,668,000Source | 489,268,000Source | 752,772,000Source | 453,271,000Source | 311,930,000Source | 244,534,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 3,324,000Source | 4,197,000Source | 14,685,000Source | 17,317,000Source | 20,051,000Source | 16,364,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 19,820,000Source | 79,635,000Source | 48,233,000Source | 12,645,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 10,824,000Source | 11,448,000Source | 9,576,000Source | 11,394,000Source | 10,308,000Source | 12,450,000Source | 44,960,000Source | 42,701,000Source | 31,206,000Source | 26,905,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 160,000Source | 175,000Source | 147,000Source | 163,000Source | 151,000Source | 166,000Source | 647,000Source | 700,000Source | 3,246,000Source | 1,663,000Source |
| Amortization of Intangible AssetsUSD | — | — | 5,961,000Source | 5,961,000Source | 5,961,000Source | 5,961,000Source | 5,961,000Source | 5,961,000Source | 23,845,000Source | 23,845,000Source | 23,845,000Source | 22,966,000Source |
| DepreciationUSD | — | — | — | — | — | — | 7,000Source | 7,000Source | — | 267,000Source | 514,000Source | 419,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | -9,766,000Source | — |
| General and Administrative ExpenseUSD | — | — | 29,807,000Source | 28,587,000Source | 28,050,000Source | 33,924,000Source | 32,507,000Source | 31,243,000Source | 152,536,000Source | 110,352,000Source | 95,289,000Source | 84,017,000Source |
| Income Tax Expense (Benefit)USD | — | — | 16,625,000Source | 16,077,000Source | 17,834,000Source | 9,861,000Source | 7,199,000Source | 11,617,000Source | 56,377,000Source | 46,311,000Source | 44,543,000Source | -76,782,000Source |
| InterestExpenseNonoperatingUSD | — | — | 3,621,000Source | 4,348,000Source | 3,070,000Source | 3,646,000Source | 3,234,000Source | 3,836,000Source | 14,649,000Source | 17,496,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 50,865,000Source | 46,093,000Source | 75,431,000Source | 39,776,000Source | 32,488,000Source | 45,560,000Source | 158,687,000Source | 145,493,000Source | 128,853,000Source | 181,468,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | 128,853,000Source | 181,468,000Source |
| Operating ExpensesUSD | — | — | 114,318,000Source | 81,550,000Source | 108,766,000Source | 114,156,000Source | 133,584,000Source | 96,494,000Source | 461,642,000Source | 367,093,000Source | 268,756,000Source | 234,188,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -106,000Source | -124,000Source | -53,000Source | -193,000Source | -127,000Source | -276,000Source | -680,000Source | -68,000Source | 159,000Source | 169,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 200,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 347,000Source | 4,706,000Source | 10,205,000Source | 6,501,000Source | 5,055,000Source | 8,841,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 239,455,000Source | 186,038,000Source | 261,280,000Source | 200,489,000Source | 215,387,000Source | 184,733,000Source | 868,453,000Source | 714,734,000Source | 582,022,000Source | 437,855,000Source |
| Cost of RevenueUSD | — | — | 59,650,000Source | 42,778,000Source | 63,198,000Source | 38,153,000Source | 44,512,000Source | 31,994,000Source | 198,342,000Source | 156,815,000Source | 121,236,000Source | 83,481,000Source |
| Operating Income (Loss)USD | — | — | 65,487,000Source | 61,710,000Source | 89,316,000Source | 48,180,000Source | 37,291,000Source | 56,245,000Source | 208,469,000Source | 190,826,000Source | 192,030,000Source | 120,186,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -106,000Source | -124,000Source | -53,000Source | -193,000Source | -127,000Source | -276,000Source | -680,000Source | -68,000Source | 159,000Source | 169,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 67,490,000Source | 62,170,000Source | 93,265,000Source | 49,637,000Source | 39,687,000Source | 57,177,000Source | 215,064,000Source | 191,804,000Source | 173,396,000Source | 104,686,000Source |
| Income Tax Expense (Benefit)USD | — | — | 16,625,000Source | 16,077,000Source | 17,834,000Source | 9,861,000Source | 7,199,000Source | 11,617,000Source | 56,377,000Source | 46,311,000Source | 44,543,000Source | -76,782,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 50,865,000Source | 46,093,000Source | 75,431,000Source | 39,776,000Source | 32,488,000Source | 45,560,000Source | 158,687,000Source | 145,493,000Source | 128,853,000Source | 181,468,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.88Source | 0.81Source | 1.3Source | 0.69Source | 0.56Source | 0.79Source | 2.76Source | 2.56Source | 2.17Source | 3.07Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.87Source | 0.79Source | 1.28Source | 0.68Source | 0.55Source | 0.78Source | 2.71Source | 2.51Source | 2.13Source | 2.97Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 57,550,902Source | 56,870,234Source | 57,933,818Source | 57,469,775Source | 57,819,060Source | 57,309,938Source | 57,492,277Source | 56,885,455Source | 59,469,648Source | 59,173,121Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 58,717,910Source | 58,103,963Source | 58,755,359Source | 58,427,134Source | 58,776,297Source | 58,524,566Source | 58,544,570Source | 57,869,915Source | 60,372,397Source | 61,097,045Source |
| Interest Expense (non-operating)USD | — | — | 3,621,000Source | 4,348,000Source | 3,070,000Source | 3,646,000Source | 3,234,000Source | 3,836,000Source | 14,649,000Source | 17,496,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 5,961,000Source | 5,961,000Source | 5,961,000Source | 5,961,000Source | 5,961,000Source | 5,961,000Source | 23,845,000Source | 23,845,000Source | 23,845,000Source | 22,966,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 15,678,000Source | 74,311,000Source | 57,962,000Source | 9,161,000Source |
| General and Administrative ExpenseUSD | — | — | 29,807,000Source | 28,587,000Source | 28,050,000Source | 33,924,000Source | 32,507,000Source | 31,243,000Source | 152,536,000Source | 110,352,000Source | 95,289,000Source | 84,017,000Source |
| Gross ProfitUSD | — | — | 179,805,000Source | 143,260,000Source | 198,082,000Source | 162,336,000Source | 170,875,000Source | 152,739,000Source | 670,111,000Source | 557,919,000Source | 460,786,000Source | 354,374,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 23,757,000Source | — |
| Interest Expense, DebtUSD | — | — | 3,620,000Source | 4,348,000Source | 3,070,000Source | 3,646,000Source | 3,234,000Source | 3,836,000Source | 14,649,000Source | 17,496,000Source | 23,757,000Source | 18,795,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | — | -15,669,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | 128,853,000Source | 181,468,000Source |
| Operating ExpensesUSD | — | — | 114,318,000Source | 81,550,000Source | 108,766,000Source | 114,156,000Source | 133,584,000Source | 96,494,000Source | 461,642,000Source | 367,093,000Source | 268,756,000Source | 234,188,000Source |
| Research and Development ExpenseUSD | — | — | 54,962,000Source | 25,387,000Source | 46,596,000Source | 50,159,000Source | 69,383,000Source | 34,540,000Source | 189,594,000Source | 145,825,000Source | 76,063,000Source | 70,886,000Source |
| Selling and Marketing ExpenseUSD | — | — | 29,549,000Source | 27,576,000Source | 34,120,000Source | 30,073,000Source | 31,694,000Source | 30,711,000Source | 119,512,000Source | 110,916,000Source | 97,404,000Source | 79,285,000Source |
Filing attachments
hrmy-ex99d1.htm · 8-K · 2026-11-04
Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending Dose Study Reinforces Favorab…
Read attachment ↗hrmy-ex99d2.htm · 8-K · 2026-11-04
Copyright © 2026 Harmony Biosciences. All rights reserved. Q3 2026 Financial Results and Business Update November 4, 2026 ────────────────────────────────────────────────────────────── Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements,…
Read attachment ↗hrmy-ex99d1.htm · 8-K · 2026-10-13
Exhibit 99.1 Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027. Current CEO Jeffrey M. Dayno, M.D., will retire at the end of the year following a nine-year tenure at the Company, including as Chief Medical Officer, and step down as a member of the B…
Read attachment ↗hrmy-20260804xex99d1.htm · 8-K · 2026-08-04
EX-99.1 2 hrmy-20260804xex99d1.htm EX-99.1 Exhibit 99.1 Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1. 0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Sa…
Read attachment ↗hrmy-20260804xex99d2.htm · 8-K · 2026-08-04
EX-99.2 3 hrmy-20260804xex99d2.htm EX-99.2 Copyright © 2026 Harmony Biosciences. All rights reserved. Q2 2026 Financial Results and Business Update August 4, 2026 ────────────────────────────────────────────────────────────── Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact sh…
Read attachment ↗hrmy-20260716xex99d1.htm · 8-K · 2026-07-16
EX-99.1 3 hrmy-20260716xex99d1.htm EX-99.1 Exhibit 99.1 Harmony Biosciences PREANNOUNCES Record QuarterLY Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026 Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026 PLYMOUTH MEETING, Pa. - July 16, 2026 -…
Read attachment ↗